🟢 Summit Therapeutics is trading 10.3% up today after Akeso announced statistically significant overall-survival improvement

Summit Therapeutics is trading 10.3% up now at $16.10 after partner Akeso announced statistically significant overall-survival improvement for ivonescimab versus pembrolizumab in Phase III HARMONi-2.

• Akeso announced the update on September 2, 2026; the study evaluated patients with PD-L1-positive advanced or metastatic non-small-cell lung cancer.
• Numerical survival data were not disclosed and are expected at a future medical conference.
• The update was the primary catalyst amid broader risk-on and biotechnology-sector strength.